Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Etienne Ouellet"'
Publikováno v:
Ocular Oncology and Pathology. 4:254-260
Background: The liver is the most common site for metastases of several primary malignancies including uveal melanoma. Methods: Review of imaging characteristics of incidental common benign liver lesions including hepatic cyst, hemangioma, focal nodu
Publikováno v:
Digestive Diseases and Sciences. 62:2293-2297
Autor:
Etienne Ouellet, Charles Ouellet, Donald Poirier, René Maltais, Patrick Lagüe, Xavier Barbeau
Publikováno v:
European Journal of Medicinal Chemistry. 119:169-182
Steroid sulfatase (STS), the enzyme which converts inactive sulfated steroid precursors into active hormones, is a promising therapeutic target for the treatment of estrogen-sensitive breast cancer. We report herein the synthesis and in vitro study o
Publikováno v:
Current Enzyme Inhibition. 10:39-53
Publikováno v:
Tetrahedron Letters. 52:5047-5050
A mild, general and efficient method for the oxidative rearrangement of 2-furylcarbamates to N-Boc-5-hydroxypyrrol-2(5H)-ones is reported. The feasibility of removing the Boc group from the products was demonstrated by the synthesis of two hitherto u
Autor:
Etienne Ouellet, Donald Poirier
Publikováno v:
Synlett. 2011:2025-2028
Publikováno v:
Investigational new drugs. 33(1)
Selective estrogen receptor modulators (SERMs) are currently in use in the hormonal therapy of breast cancer. In that respect, a new hormone-related approach is the therapeutical inhibition of steroid sulfatase (STS), which converts inactive, sulfate
Publikováno v:
ChemInform. 43
A mild, general and efficient method for the oxidative rearrangement of 2-furylcarbamates to N-Boc-5-hydroxypyrrol-2(5H)-ones is reported. The feasibility of removing the Boc group from the products was demonstrated by the synthesis of two hitherto u
Autor:
Donald Poirier, Etienne Ouellet
Publikováno v:
ChemInform. 43
Publikováno v:
Bioorganicmedicinal chemistry letters. 21(18)
A non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) was designed based on a modified 3-hydroxy-estra-1,3,5(10)-triene core having an additional five-member lactone ring and a benzamide group. The inhibitor was synthesiz